Nature Medicine: AMPLIFY-201 Final Results — ELI-002 2P KRAS Amphiphile Vaccine Delivers Durable Relapse-Free Survival in Pancreatic and Colorectal Cancer
Final phase 1 AMPLIFY-201 results published in Nature Medicine report that ELI-002 2P — a lymph node-targeted vaccine combining amphiphile-modified mutant KRAS G12D/G12R peptides with CpG-7909 adjuvant — produced durable responses in 25 patients with minimal residual mKRAS disease (20 pancreatic, 5 colorectal). At 19.7 months median follow-up, robust T-cell responders achieved median relapse-free survival not reached vs. 3.02 months in non-responders (HR 0.12, p=0.0002); 71% of evaluable patients generated both CD4+ and CD8+ T cells, and antigen spreading was observed in 67%. Phase 2 enrollment of the next-generation 7-peptide formulation ELI-002 7P is complete, with results expected in 2026.